1 Moravvej Z, "Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains" 42 : 370-371, 2013
2 Gu B, "The emerging problem of linezolid-resistant Staphylococcus" 68 : 4-11, 2013
3 Moellering RC Jr., "Tedizolid: a novel oxazolidinone for Gram-positive infections" 58 (58): S1-3, 2014
4 Kisgen JJ, "Tedizolid: a new oxazolidinone antimicrobial" 71 : 621-633, 2014
5 Mendes RE, "Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States" 58 : 1243-1247, 2014
6 Rajan S, "Skin and soft-tissue infections: classifying and treating a spectrum" 79 : 57-66, 2012
7 "Sivextro (tedizolid) Prescribing information" Cubist Pharmaceuticals 2014
8 Rubinstein E, "Pneumonia caused by methicillin-resistant Staphylococcus aureus" 46 (46): S378-385, 2008
9 Rodríguez-Avial I, "In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci" 67 : 167-169, 2012
10 Shaw KJ, "In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains" 52 : 4442-4447, 2008
1 Moravvej Z, "Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains" 42 : 370-371, 2013
2 Gu B, "The emerging problem of linezolid-resistant Staphylococcus" 68 : 4-11, 2013
3 Moellering RC Jr., "Tedizolid: a novel oxazolidinone for Gram-positive infections" 58 (58): S1-3, 2014
4 Kisgen JJ, "Tedizolid: a new oxazolidinone antimicrobial" 71 : 621-633, 2014
5 Mendes RE, "Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States" 58 : 1243-1247, 2014
6 Rajan S, "Skin and soft-tissue infections: classifying and treating a spectrum" 79 : 57-66, 2012
7 "Sivextro (tedizolid) Prescribing information" Cubist Pharmaceuticals 2014
8 Rubinstein E, "Pneumonia caused by methicillin-resistant Staphylococcus aureus" 46 (46): S378-385, 2008
9 Rodríguez-Avial I, "In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci" 67 : 167-169, 2012
10 Shaw KJ, "In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains" 52 : 4442-4447, 2008
11 US Food and Drug Administration, "Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment"
12 Yum JH, "Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea" 54 : 5381-5386, 2010
13 Goldstein EJ, "Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin" 53 : 1074-1080, 2011
14 Brook I, "Antianaerobic antimicrobials: spectrum and susceptibility testing" 26 : 526-546, 2013
15 Thomson KS, "Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins" 57 : 2892-2895, 2013